Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity.

Amini A. et al, (2024), Current opinion in virology, 67

Single-cell analysis of human MAIT cell transcriptional, functional and clonal diversity

Garner LC. et al, (2023), Nature Immunology, 24, 1565 - 1578

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75

Huo J. et al, (2023), Cell Reports, 42, 111903 - 111903

Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant

Murray SM. et al, (2022), British Journal of Haematology, 198, 668 - 679

Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers

Phillips E. et al, (2022), Clinical and Experimental Immunology, 209, 90 - 98

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13

Evolution of long-term vaccine induced and hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study

Moore SC. et al, (2022)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18

Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Tuekprakhon A. et al, (2022)

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

Ogbe A. et al, (2021), Nature Communications, 12

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

Skelly DT. et al, (2021), Nature Communications, 12

T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study

Angyal A. et al, (2021), SSRN Electronic Journal

Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021)

Include forthcoming?